The 2023 SITC-Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship from the Society for Immunotherapy of Cancer (SITC) with funding from Mallinckrodt Pharmaceuticals, supports a postdoctoral researcher, resident, research scientist, or comparable position, working on furthering research and translation of adverse events in cancer immunotherapy. Applicants must be a member of the SITC and hold an MD, PhD or MD/PhD degree. Applications are open to candidates worldwide. The fellowship provides funding of 40,000 USD over 1 year plus financial support to attend SITC´s 38th Annual Meeting.
Applications close on March 27, 2023.